PRCT (PROCEPT BioRobotics) Ending Cash Position: $248.7 Mil (As of Mar. 2026)


PRCT PROCEPT BioRobotics Corp PRCT
70 GF Score
Price $21.15
GF Value $92.79
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Ending Cash Position?

PROCEPT BioRobotics PRCT -0.26% 70 Ending Cash Position is $248.7 Mil as of Mar. 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $92.79 (Significantly Undervalued). The stock has 2 warning signs investors should review.

PROCEPT BioRobotics's Ending Cash Position for the quarter that ended in Mar. 2026 was $248.7 Mil.

PROCEPT BioRobotics's quarterly Ending Cash Position declined from Sep. 2025 ($297.3 Mil) to Dec. 2025 ($289.5 Mil) and declined from Dec. 2025 ($289.5 Mil) to Mar. 2026 ($248.7 Mil).

PROCEPT BioRobotics's annual Ending Cash Position increased from Dec. 2023 ($260.3 Mil) to Dec. 2024 ($336.8 Mil) but then declined from Dec. 2024 ($336.8 Mil) to Dec. 2025 ($289.5 Mil).

PROCEPT BioRobotics Ending Cash Position Related Terms

PROCEPT BioRobotics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for PROCEPT BioRobotics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics Ending Cash Position Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 305.10 225.67 260.26 336.76 289.54

PROCEPT BioRobotics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 319.25 305.76 297.32 289.54 248.68
PRCT
70GF Score
PROCEPT BioRobotics Corp PRCT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROCEPT BioRobotics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

PROCEPT BioRobotics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=336.763+-47.222
=289.5

PROCEPT BioRobotics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=289.54+-40.861
=248.7

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $248.7 Mil mean?
PROCEPT BioRobotics (PRCT) has a Ending Cash Position of $248.7 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PROCEPT BioRobotics and its competitors.
Is PROCEPT BioRobotics' Ending Cash Position too high?
PROCEPT BioRobotics' current Ending Cash Position is $248.7 Mil. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Ending Cash Position compare to ENOV and INSP?
PROCEPT BioRobotics' Ending Cash Position of $248.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current Ending Cash Position is $248.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $92.79, compared to a current price of $21.15 — trading 77.2% below its estimated fair value. The current Ending Cash Position is $248.7 Mil. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Ending Cash Position is $248.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of $21.15 is trading 77.2% below its estimated GF Value™ of $92.79. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for PRCT:

  • Ending Cash Position: $248.7 Mil
  • GF Value™: $92.79 vs. price of $21.15 (77.2% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:Mexico
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score

Get the complete analysis for PRCT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.15
Price
$92.79
GF Value